Philippe Rougier

Q: What Schools Are Affiliated With Philippe Rougier

Philippe Rougier is affiliated with the following schools: Flinders University, Marche Polytechnic University, Hannover Medical School, University of Turin, University of Vienna, University of Southampton

Philippe Rougier's AcademicInfluence.com Rankings

Philippe Rougier

Medical

#2008

World Rank

#2397

Historical Rank

Oncology

#107

World Rank

#111

Historical Rank

medical Degrees

Philippe Rougier

Philosophy

#5890

World Rank

#8817

Historical Rank

Logic

#3102

World Rank

#4212

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Philippe Rougier's Degrees

PhD Medical Oncology Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Philippe Rougier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Philippe Rougier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial (2000) (3236)
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. (2009) (2856)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. (2006) (2217)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. (2011) (1721)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (2008) (1716)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (2014) (1712)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (2008) (1528)
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. (2011) (1345)
Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. (1997) (1130)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. (2001) (1025)
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998) (994)
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. (1998) (978)
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. (1997) (938)
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. (2013) (897)
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. (2000) (771)
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. (2010) (733)
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. (2009) (687)
Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases (2006) (675)
Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial (2010) (647)
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. (2015) (646)
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. (2008) (597)
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. (2008) (543)
Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. (1992) (543)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. (2012) (540)
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of (2000) (539)
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. (2006) (531)
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. (2002) (513)
Complete response of colorectal liver metastases after chemotherapy: does it mean cure? (2006) (500)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. (2006) (497)
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. (1998) (469)
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin (1999) (462)
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. (2012) (449)
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. (2002) (448)
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. (1996) (441)
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. (1997) (438)
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy (2001) (435)
KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience (2008) (418)
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials (2004) (399)
Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. (2015) (399)
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. (2009) (374)
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (366)
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012) (330)
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. (2005) (329)
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. (1998) (297)
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. (2002) (284)
Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial (2008) (279)
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial (2007) (275)
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. (2007) (270)
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. (2004) (270)
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. (2005) (249)
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. (2004) (240)
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. (2014) (224)
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. (2012) (223)
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. (2001) (218)
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. (2008) (217)
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. (1996) (200)
Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases (2005) (192)
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). (2012) (190)
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre (2014) (189)
Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer (1995) (185)
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors (2000) (185)
Free Human Chorionic Gonadotropin β Subunit in Gonadal and Nongonadal Neoplasms (1992) (184)
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. (1996) (181)
Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study (2009) (174)
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. (1982) (173)
Transcatheter chemoembolization of progressive carcinoid liver metastasis. (1993) (170)
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. (1998) (162)
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. (2009) (156)
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. (2013) (152)
Perioperative FOLFOX 4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC 40983 ) : long-term results of a randomised , controlled , phase 3 trial (2013) (152)
Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide (2004) (149)
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. (2011) (145)
Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). (2005) (144)
Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. (2013) (142)
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. (2005) (140)
Prognostic factors in primary gastrointestinal non‐Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature (1989) (137)
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? (2004) (134)
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. (1995) (134)
Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. (1998) (132)
The ratio of metastatic to examined lymph nodes is a powerful independent prognostic factor in rectal cancer (2008) (131)
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
Pulmonary resection for metastases of colorectal adenocarcinoma. (2010) (128)
Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles (1992) (128)
Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer): Revised Bethesda Guidelines-Based Approach Versus Molecular Screening (2008) (128)
A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. (2005) (126)
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. (2004) (125)
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. (2002) (124)
The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. (2011) (121)
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. (2005) (120)
Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. (2009) (117)
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. (2009) (117)
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer]. (1999) (116)
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. (1994) (115)
Chemotherapy in the Treatment of Neuroendocrine Malignant Tumors (2000) (115)
Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. (1985) (113)
Liver abscess formation after local treatment of liver tumors (1996) (111)
Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. (2004) (105)
CPT-11 (irinotecan) in the treatment of colorectal cancer. (1995) (104)
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. (1999) (103)
Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. (1995) (101)
Repeat hepatectomy for cancer (1993) (99)
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. (2009) (97)
Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) (2012) (95)
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. (2002) (95)
Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. (2010) (94)
Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours (2006) (94)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. (2004) (93)
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. (2010) (92)
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. (2015) (92)
Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402). (2008) (91)
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. (2008) (90)
Medullary thyroid carcinoma: prognostic factors and treatment. (1983) (89)
New directions in the treatment of colorectal cancer: a look to the future. (2000) (88)
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. (2016) (87)
Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer. (1998) (86)
Extensive molecular screening for hereditary non-polyposis colorectal cancer (2000) (85)
Pancreatic metastases: a multicentric study of 22 patients. (2004) (85)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial. (2014) (85)
Epidemiology, treatment and chemoprevention in colorectal cancer. (2003) (84)
Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy (2011) (83)
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure (2000) (80)
Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. (1992) (80)
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. (2002) (79)
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial (1998) (78)
Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group. (1993) (78)
Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. (1989) (78)
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model (2004) (76)
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) (2010) (76)
Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. (1994) (76)
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
Thirteen-Month Registration of Patients with Gastroenteropancreatic Endocrine Tumours in France (2008) (72)
Paromomycin: an effective treatment for cryptosporidial diarrhea in patients with AIDS. (1994) (72)
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. (2011) (72)
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. (1993) (71)
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases (2007) (69)
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. (2010) (64)
Nodular regenerative hyperplasia of the liver: Report of six cases and review of the literature (1978) (64)
CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. (1996) (64)
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials (2008) (64)
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. (2008) (64)
Hepatocellular carcinoma (HCC): an update. (2007) (64)
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. (2008) (63)
Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. (1999) (63)
Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. (2009) (62)
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. (2007) (62)
Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians (2016) (62)
Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. (1994) (62)
Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study. (1997) (62)
Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. (2006) (61)
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. (2013) (59)
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer (2010) (58)
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. (2012) (58)
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). (2002) (57)
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma† (2016) (57)
Chemotherapy in elderly patients with colorectal cancer. (2008) (54)
Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. (1999) (53)
Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. (1994) (52)
5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. (1997) (51)
Preoperative chemotherapy of locally advanced gastric cancer. (1994) (51)
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. (2005) (51)
Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. (1991) (50)
Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases (2012) (50)
Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. (1997) (49)
Assessment of patent foramen ovale in carcinoid heart disease. (2006) (48)
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study (2009) (48)
Liver metastases from colorectal cancer: the turning point. (2002) (47)
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study (2009) (46)
The timing of chemotherapy and surgery for the treatment of colorectal liver metastases. (2010) (44)
No evidence of somatic FGFR3 mutation in various types of carcinoma (2001) (43)
Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. (2012) (42)
6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status (2009) (42)
Impact of Chemotherapy on the Accuracy of Computed Tomography Scan for the Evaluation of Colorectal Liver Metastases (2009) (41)
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. (2006) (41)
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. (2000) (41)
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. (1993) (41)
[Breast cancer in the early stage]. (2012) (39)
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. (2006) (38)
EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. (2012) (38)
Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. (1995) (37)
Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. (2004) (37)
Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. (1996) (37)
Thyroid iodine content measured by x-ray fluorescence in amiodarone-induced thyrotoxicosis: concise communication. (1983) (35)
Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma (2012) (35)
Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature. (1978) (34)
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. (1997) (33)
Medical treatments for hepatocellular carcinoma (HCC): what's next? (2006) (33)
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. (2018) (32)
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases (2004) (31)
The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. (2006) (31)
Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results (2007) (31)
Meta-Analysis of Randomised Trials Comparing Gemcitabine-Based Doublets versus Gemcitabine Alone in Patients with Advanced and Metastatic Pancreatic Cancer (2007) (31)
Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. (2011) (30)
3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC) (2007) (30)
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. (1993) (30)
Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. (1997) (30)
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. (2000) (30)
Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. (2011) (30)
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study. (1987) (29)
Prevalence of patent foramen ovale and usefulness of percutaneous closure device in carcinoid heart disease. (2008) (29)
Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. (2009) (29)
Plasma viraemia as a marker of viral replication in HIV-infected individuals. (1991) (28)
Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab (2008) (28)
Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma (2015) (27)
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. (2003) (27)
Echocardiographic follow-up of treated patients with carcinoid syndrome. (2010) (26)
5‐Fluorouracil, doxorubicin, and cisplatin regimen in adrenal cortical carcinoma (1988) (26)
Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits (1996) (26)
[Pseudo-continent perineal colostomies after amputation of the rectum for cancer]. (1993) (25)
Prolonged survival after resection of pancreatoblastoma and synchronous liver metastases in an adult. (2001) (25)
A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma. (1997) (25)
Relevance of the quantitative detection of HIV proviral sequences in PBMC of infected individuals. (1992) (25)
Nonsurgical methods for liver metastases including cryotherapy, radiofrequency ablation, and infusional treatment: what's new in 2001? (2002) (25)
Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) (2005) (25)
Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies. (2011) (25)
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. (1991) (24)
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. (1995) (24)
Hepatic arterial infusion in the management of colorectal cancer liver metastasis: Current and future perspectives. (2017) (24)
Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer: Meta-analysis of four trials investigating 5-FU and irinotecan. (2006) (23)
The treatment of undifferentiated neuroendocrine tumors. (2001) (23)
Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. (2011) (23)
Portal triad clamping (TC) or hepatic vascular exclusion (VE) for major liver resection after prolonged neoadjuvant chemotherapy? A case-matched study in 60 patients. (2006) (22)
Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. (2006) (22)
Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study (2017) (22)
[Recommendations for the management of GIST patients]. (2005) (22)
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. (2016) (22)
[Peritoneal carcinosis treated by complete excision and immediate postoperative intra-peritoneal chemotherapy. Phase II study in 54 patients]. (1997) (22)
Trimethoprim-sulphamethoxazole rechallenge in 20 previously allergic HIV-infected patients after homeopathic. (1995) (22)
Intra‐Arterial Hepatic Chemotherapy with Pirarubicin: Preclinical and Clinical Studies (1990) (22)
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. (2015) (21)
Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome (2012) (21)
Risk of venous thrombosis in patients with pancreatic adenocarcinoma. (2007) (21)
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. (2014) (21)
Second-line treatment of patients with metastatic colorectal cancer. (2005) (20)
[Chemotherapy for medullary cancer of the thyroid. Phase II trials with adriamycin and cis-platinum administered as monochemotherapy]. (1984) (20)
[Intravenous chemotherapy with streptozotocin and 5 fluorouracil for hepatic metastases of Zollinger-Ellison syndrome. A prospective multicenter study in 21 patients]. (1991) (20)
Cutaneous Perianal Recurrence on the Site of Lone Star Retractor™ after J-pouch Coloanal Anastomosis for Rectal Cancer: Report of Two Cases (2008) (20)
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study. (1996) (20)
Multimodal treatment of oesophageal cancer (2007) (19)
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. (2015) (19)
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. (1997) (19)
Docetaxel delivers new management opportunities for gastrointestinal carcinomas (1995) (19)
Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial. (2006) (19)
Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. (2006) (18)
Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases. (2013) (18)
Metastatic colorectal cancer: first- and second-line treatment in 2005. (2005) (18)
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. (1997) (18)
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. (2011) (18)
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort (2014) (17)
Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study. (2016) (17)
Colorectal cancer chemotherapy: irinotecan. (2000) (17)
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. (2005) (17)
103 Radiotherapy with concomitant chemotherapy superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the EORTC radiotherapy and gastrointestinal tract cooperative groups (1996) (17)
A simplified surgical technical procedure for intra-arterial chemotherapy in secondary liver cancer. Experience in 50 patients. (1987) (16)
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial]. (2011) (16)
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. (2014) (16)
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. (2005) (16)
Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: feasibility and potential benefits in a retrospective series of 117 patients. (2009) (16)
Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study (2016) (16)
Evolution of thyroid 127I stores measured by X-ray fluorescence in subacute thyroiditis. (1982) (16)
Comparison of prognostic value of tissue Doppler imaging in carcinoid heart disease versus the value in patients with the carcinoid syndrome but without carcinoid heart disease. (2010) (15)
A pooled safety and efficacy analysis examining the effect of performance status (PS) on outcomes in nine first-line treatment (rx) trials (cts) of 6,286 patients (pts) with metastatic colorectal cancer (MCRC) (2007) (15)
Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer -A pooled analysis of 254 patients included in 2 randomised trials. (2004) (15)
Review of the role of CPT-11 in the treatment of colorectal cancer. (2001) (15)
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. (2016) (15)
Treatment sequence of synchronously (liver) metastasized colon cancer. (2016) (15)
RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma: Quality-of-life (QoL) results. (2014) (14)
Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. (1993) (14)
The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 (2013) (14)
Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg (1998) (14)
Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases. (1994) (13)
Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses (1994) (13)
Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? The case of liver metastases from colorectal cancer. (1998) (13)
Detection of pre-S1 proteins in peripheral blood mononuclear cells from patients with HBV infection. (1991) (13)
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). (2006) (13)
Cetuximab Therapy in Colorectal Cancer Mutation Status Is Predictive of Response to KRAS Updated (2006) (13)
Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer. (1999) (13)
Systemic chemotherapy of advanced digestive neuroendocrine tumours. (1999) (13)
The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri (2008) (13)
Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies. (2011) (12)
O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial (2012) (12)
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). (2018) (12)
Pharmacology and antitumour effects of intraportal pirarubicin on experimental liver metastases. (1993) (12)
Review article: benefits and risks of chemotherapy in elderly patients with metastatic colorectal cancer (2009) (11)
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. (2017) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort. (2015) (11)
289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC) (2003) (11)
[Is the aggressive treatment of locoregional recurrences of colorectal cancers justified?]. (1991) (11)
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study (2015) (11)
[Resectable liver metastases and synchronous extra-hepatic sites of colorectal origin. Surgical indications]. (1993) (11)
[Anatomo-pathologic study of hepatic toxicity in intra-arterial hepatic chemotherapy]. (1989) (10)
Anatomical basis for pancreatic locoregional chemotherapy (1992) (10)
3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results (2007) (10)
Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study (2001) (10)
Application of X-ray fluorescence to the study of iodine distribution and content in the thyroid (2004) (10)
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. (1998) (10)
[Therapeutic management of hepatic metastases from colorectal cancers]. (2003) (10)
Acute myocardiotoxicity during 5-fluorouracil therapy (2005) (9)
Chemotherapy plus cetuximab in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: A pooled analysis of the CRYSTAL and OPUS studies (2012) (9)
Chemotherapy as initial treatment of locally advanced unresectable pancreatic cancer: a valid option? (2007) (9)
Double pancreatic and gastric adenocarcinomas: a rare association. (2013) (9)
Abdominoperineal resection combined with pre- and postoperative radiation therapy in the treatment of low-lying rectal carcinoma. (1997) (9)
Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. (2012) (9)
The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer. (2007) (9)
Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer - a pooled analysis of clinical trials. (2004) (9)
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. (1992) (9)
[Intraperitoneal hyperthermic chemotherapy (IPHC), a promising treatment of peritoneal carcinomatosis]. (1994) (9)
[Another failure in the attempt of definition of the indications to the resection of liver metastases of colorectal origin]. (1992) (9)
KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab. (2007) (9)
Irinotecan in combination with new agents (2004) (9)
Management of patients over 80 years of age treated with resection for localised colon cancer: results from a French referral centre. (2014) (9)
Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. (1987) (8)
[The role of PET scan in gastrointestinal stromal tumors]. (2007) (8)
[Sclerosing cholangitis after chemotherapy by continuous hepatic intra-arterial infusion of fluorodeoxyuridine]. (1986) (8)
Erratum to: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-acryl Microspheres: Embozar (EMBOsphere + ZAnosaR) Study (2017) (8)
In vivo drug intracellular localisation by analytical ion microscopy: preliminary study in gastric adenocarcinomas treated with 5-fluorouracil. (1991) (8)
Chemotherapy and medical treatment of hepatocellular carcinoma (HCC). (1998) (8)
[Colorectal cancer management]. (2004) (8)
A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results. (2009) (8)
Absence of somatic alterations of the EB1 gene adenomatous polyposis coli-associated protein in human sporadic colorectal cancers. (1998) (8)
Elderly colorectal cancer patients are under treated (2004) (8)
Characteristics, prognosis and treatments of 294 patients with poorly differentiated neuroendocrine carcinoma: The FFCD-GTE national cohort. (2015) (8)
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†. (2015) (8)
Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial. (2009) (8)
[Role of radiotherapy in the treatment of medullary cancer of the thyroid]. (1984) (7)
709PD FIVE-YEAR RESULTS OF THE RANDOMIZED PHASE III TRIAL COMPARING S-1 MONOTHERAPY VERSUS SURGERY ALONE FOR STAGE II/III GASTRIC CANCER PATIENTS AFTER CURATIVE D2 GASTRECTOMY (ACTS-GC STUDY) (2010) (7)
Current controversies in cancer : Is there a standard adjuvant treatment for colon cancer? (1998) (7)
Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. (2016) (7)
Tumeurs endocrines digestives (2010) (7)
[Cutaneomucous adverse effects of continuous infusion of 5-fluorouracil: 12 cases]. (1988) (7)
Complete radiological response of colorectal liver metastases (LM) after chemotherapy: Does it mean cure? (2006) (7)
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin. (1989) (7)
Systemic and local chemotherapy in palliative and adjuvant treatment of hepatic metastases of colorectal origin (1992) (7)
Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl) (2012) (7)
[Stomach adenocarcinomas: comparison between CA 19-9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment]. (1992) (7)
Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer. (1994) (6)
Meta-analysis of anti-VEGF class adverse events from three double-blind (Db) placebo (Pbo)-controlled phase III trials with IV aflibercept (Afl). (2012) (6)
[Single and multifactorial prognostic study of 400 operated rectal adenocarcinomas]. (1993) (6)
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial. (2016) (6)
[Unusual cause of ascites: the POEMS syndrome]. (1990) (6)
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment (2009) (6)
Digestive neuroendocrine tumors (DNET): the era of targeted therapies. (2013) (6)
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. (1999) (6)
Irinotecan for the treatment of gastric cancer (2004) (6)
[Rectal lymphoma: endorectal ultrasound aspect]. (1992) (6)
[Epidermoid cancers of the operated esophagus. High incidence of associated neoplasia]. (1992) (6)
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]. (2002) (6)
Patent foramen ovale in carcinoid heart disease. (2010) (6)
[Control of perfusion by angioscintigraphy during hepatic intra-arterial chemotherapy]. (1989) (6)
Thermic homogeneity and standardization of intraperitoneal chemohyperthermia for peritoneal carcinomatosis (1996) (6)
[Gastric adenocarcinoma surgically treated. A multivariate analysis of prognostic factors]. (1988) (6)
Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report (2017) (6)
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). (2013) (6)
[Hepatic intra-arterial chemotherapy of isolated metastases of colo-rectal adenocarcinoma]. (1986) (6)
Cancer of the rectum (2001) (6)
[Surgical treatment of medullary thyroid cancer]. (1984) (5)
A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group (2017) (5)
Carcinoma of the colon (2001) (5)
[What are the real indications for hepatectomies in metastases of colorectal origin?]. (1998) (5)
Tomographie par émission de positons et cancers digestifs (2008) (5)
Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials (2007) (5)
Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO. (2015) (5)
Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression. (2011) (5)
Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study. (1991) (5)
Esophageal squamous cell carcinoma: the specific limited place of surgery defined by a prospective multivariate study of prognostic factors after surgical approach. (1992) (5)
Palliative and adjuvant chemotherapy in colorectal cancer. (2001) (5)
[Treatment of epidermoid cancer of the esophagus]. (1984) (5)
[Standards, options and recommendations for the management of patients with primary adenocarcinoma of the rectum. National Federation of Centers for the Fight against Cancer]. (1999) (5)
[Rectal cancer and adjuvant chemotherapy: which conclusions?]. (2010) (5)
[Gastroduodenal complications of hepatic intra-arterial chemotherapy of hepatic metastases of colorectal origin]. (1989) (5)
Somatostatin receptor imaging: a preliminary experience in forty-nine patients. (1995) (5)
[Failure of chemotherapoy in thyroid cancers (author's transl)]. (1981) (5)
Tolerance of a triple combination therapy with zidovudine, didanosine and interferon-alpha in seven HIV-infected patients. (1995) (5)
Four-year survival in patients (pts) undergoing liver surgery after neoadjuvant triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-CET) for previously treated and unresectable liver metastases from kras wt colorectal cancer (LM-CRC) (European trial OPTILIV, NCT00852228). (2014) (4)
HYPERTHYROCALCITONINÆMIA, SCHWARTZ-BARTTER SYNDROME, AND OAT-CELL CARCINOMA (1974) (4)
Meta-analyses of randomized trials assessing the interest chemotherapy in advanced gastric cancer (2008) (4)
[Chemotherapy with curative intent before (neoadjuvant) or after (adjuvant) surgery for colorectal cancer liver metastases]. (2003) (4)
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)]. (2004) (4)
Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer. (2011) (4)
[Recommendations for the management of gastro-intestinal stromal tumors]. (2006) (4)
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. (2013) (4)
Management of Colorectal Cancer (1997) (4)
Is there a standard adjuvant treatment for colon cancer? (1998) (4)
[Use of monoclonal antibodies in the treatment of cancer of the pancreas: towards new progress?]. (1990) (4)
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer (1998) (4)
Current treatment options for advanced colorectal cancer. (2000) (4)
Autoimmune pancreatitis with atypical imaging findings that mimicked an endocrine tumor. (2010) (4)
Hepato-gastroenterologists and oncologists are complementary in the management of digestive cancers. (2011) (4)
Cetuximab efficacy in patients treated routinely in university hospitals. (2007) (3)
[Treatment of hepatocellular carcinoma in the presence of liver cirrhosis]. (1995) (3)
Cetuximab plus chemotherapy in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: A pooled analysis of the CRYSTAL and OPUS studies. (2012) (3)
Recent advances in systemic chemotherapy of metastatic colorectal cancer. (1996) (3)
[Treatment of metastatic malignant insulinomas. 2 cases]. (1995) (3)
Physiological Evaluation of Anomalous Aortic Origin of a Coronary Artery Using Computed Tomography–Derived Fractional Flow Reserve (2021) (3)
Neoadjuvant chemotherapy (NCT) in locally advanced gastric carcinoma (LAGC) (1993) (3)
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial. (2015) (3)
Renal effects of streptozocin: Preliminary results of the STREPTOTOX prospective study. (2014) (3)
[Value of endorectal ultrasonography in the treatment of rectal tumors]. (1996) (3)
Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens (2015) (3)
Phase II and pharmacokinetic study of fotemustine in inoperable colorectal cancer. (1993) (3)
[Use of tomographic scintigraphy with radio-labelled monoclonal antibodies for detecting human digestive cancers and medullary cancers of the thyroid]. (1983) (3)
Colon cancer. (2006) (3)
[Adjuvant treatment of colorectal cancers]. (1994) (3)
[Established data and practical recommendations concerning pre- and postoperative chemotherapy of rectal cancer]. (1999) (3)
[Cutaneous manifestations of POEMS syndrome]. (1989) (2)
[Desmoid tumors or intra-abdominal fibromatoses]. (1993) (2)
Clinical determinants of tumor response in patients with 5-FU based treatment for metastatic colorectal cancer. Results of a multivariate analysis of 3825 patients (2001) (2)
[Detection of protein p53 in the stool of patients with colorectal cancer]. (1997) (2)
[Colorectal cancer: what progress can we anticipate in the next few years?]. (2010) (2)
More patients needed in stage II colon cancer trials. (2000) (2)
[What can be done for patients with digestive cancer in 1999? Guidelines of the French Foundation of Digestive Cancerology (2nd part)]. (1999) (2)
Les cancers digestifs (2006) (2)
Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial. (2014) (2)
[Hepatic metastases of colorectal cancers: intra-arterial chemotherapy. Value and indications]. (1996) (2)
OP8. Economic implications of hepatic arterial infusion chemotherapy in the treatment of nonresectable colorectal liver metastases (1997) (2)
Chimiothérapie versus prothèse oesophagienne comme traitement de première intention de la dysphagie maligne des cancers de l'œsophage inopérables (2008) (2)
[The value of tumor markers in digestive oncology]. (1989) (2)
[Conference review. Colon cancer: what treatment in 2004? The point in five questions]. (2005) (2)
Radioimmunotherapy of colon carcinoma with I-131 labeled antibodies, successful experimental results and clinical dosimetry study. (1990) (2)
Definitive Results of the French FFCD-SFRO 2000-01 Study: Phase III Trial Comparing Chemoradiotherapy (Cisplatin and Infusional 5-FU) Followed by Gemcitabine vs. Gemcitabine Alone in Patients With Locally Advanced Non Metastatic Pancreatic Cancer (2007) (2)
Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1 (1997) (2)
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid]. (1983) (2)
[Major hepatectomy after intra-arterial chemotherapy for initially unresectable liver tumors. Frequency, technical problems, results and indications]. (1996) (2)
[Combination radiotherapy and chemotherapy in the treatment of locally advanced adenocarcinoma of the pancreas. Experiences of the Gustave Roussy Institute]. (1990) (2)
Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). (2010) (2)
Topoisomerase I Inhibitors: Current Use and Prospects (2012) (2)
[Medullary thyroid cancers. Prognostic factors of nonassociated sporadic forms. Therapeutic implications]. (1984) (2)
773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma (2017) (2)
[Treatment strategy for pancreatic endocrine tumours]. (2003) (2)
5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial (2004) (2)
Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). (1996) (2)
[Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)]. (1988) (2)
[Targeted biotherapy: a revolution in the management of patients with colorectal cancer?]. (2009) (2)
Title: Impact of fluorodihydroxyphenylalanine-(18F) PET on management of adult patients with documented or occult digestive endocrine tumors Short title: FDOPA PET and digestive endocrine tumors (2009) (2)
A randomized double-blind placebo-controlled study of org 2766, an acth (4–9) analogue, for the prevention of neuropathy induced by cisplatin (P) with or without vincaalcaloids (VA) combination chemotherapy (CT) (1993) (2)
gastrointestinal tumors 709 PD FIVE-YEAR RESULTS OF THE RANDOMIZED PHASE III TRIAL COMPARING S-1 MONOTHERAPY VERSUS SURGERY ALONE FOR STAGE II / III GASTRIC CANCER PATIENTS AFTER CURATIVE D 2 GASTRECTOMY ( ACTS-GC STUDY ) (2010) (2)
[Surgical interventions for erroneous diagnoses of liver metastases]. (1994) (2)
Emergency therapy for liver metastases from advanced VIPoma: surgery or transarterial chemoembolization? (2016) (2)
Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer (1988) (1)
[Rational bases and results of intra-arterial hepatic chemotherapy]. (1988) (1)
[Multiple endocrine neoplasia type 2b. Clinical, diagnostic and therapeutic aspects]. (1984) (1)
[What can be done for digestive cancer in 1999? Recommendations of the French Foundation of Digestive Cancer (1st Part)]. (1999) (1)
Multiple Endocrine Neoplasia Type 2b: Experience at Villejuif Mucosal ganglioneuromatosis medullary thyroid carcinoma and pheochromocytoma (1983) (1)
[What changes were made in the National Thesaurus of Gastrointestinal Cancer in 2005?]. (2006) (1)
Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577) (2004) (1)
Iconography : Longitudinal quality of life study in patients with metastatic gastric cancer (2008) (1)
Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC) (1999) (1)
The role of French gastroenterologists (GE) in digestive oncology: Results of a national survey (FFCD, FSMAD, AFEF, ANGH, CREGG, SFED, SNFGE). (2010) (1)
Preliminary results of a randomized phase III trial comparing streptozotocin plus fluorouracil versus interferon for metastatic carcinoid tumors (FNCLCC - FFCD 9710). (2006) (1)
[Cancer of the colon. Epidemiology, pathologic anatomy, Dukes staging, physiopathology, diagnosis, course, principles of treatment and prevention]. (1999) (1)
[Recent advances in adjuvant chemotherapy in colonic cancers]. (1997) (1)
[Prognosis and treatment of malignant digestive lymphomas. I. Primary lymphomas of the digestive tract should be treated like other malignant non-Hodgkin's lymphomas. Systematic laparotomy is not indispensable]. (1984) (1)
[Clinical signs in medullary cancers of the thyroid]. (1984) (1)
Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer: A European multicenter phase II trial. (2010) (1)
[Immunohistochemical and ultrastructural studies of thyroid cancer]. (1984) (1)
Survival after peri-operative chemotherapy with folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the eortc intergroup randomized phase III study 40983 (2007) (1)
Obesity in metastatic colorectal cancer: Pooled analysis of FFCD trials. (2016) (1)
[Role of intragastric titration (Fordtran and Walsh method) in stomach function tests]. (1978) (1)
[Epidermoid cancers of the esophagus: combined chemotherapy, surgery and radiotherapy. Preliminary results in 50 cases]. (1988) (1)
Benefit of oncologist and geriatrician collaboration in the management of digestive cancer in elderly patients (2007) (1)
Prognostic factor of recurrence for resected digestive endocrine tumors. (2009) (1)
[Measurement of intrathyroidal iodine content by X fluorescence: usefulness and application (author's transl)]. (1981) (1)
[Importance of a multidisciplinary approach to metastatic cancer of the rectum]. (1998) (1)
Final results of first European phase II trial of intravenous cetuximab (Cet) and hepatic artery infusion of irinotecan, 5-fluorouracil, and oxaliplatin in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (LM-CRC) after systemic treatment failure (OPTILIV, NCT00852228 (2013) (1)
[Efficacy of chemotherapy and combined chemo-radiotherapy in gastric adenocarcinoma]. (1989) (1)
Sandostatin® LAR® Leaders Meeting – European Neuroendocrine Tumour Network ENET (2000) (1)
IS4. Trials in Progress (2012) (1)
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG. European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. (1998) (1)
[Demonstration in a thyroid cancer of vesicular structures similar to ultimobranchial-type vesicles described in mice]. (1981) (1)
Abstract No. 151: Chemoembolization of Neuroendocrine Liver Metastases Using Streptozocin and Tris-Acryl Microspheres: Embozar Study (2009) (1)
[Primitive digestive localizations of malignant non-Hodgkin's lymphoma. Prognostic factors of locally advanced disease: stage II. Report of 67 cases]. (1990) (1)
Radiolabelled monoclonal antibodies against alpha-fetoprotein for in vivo localization of human hepatocellular carcinoma by immunotomoscintigraphy (2004) (1)
Phase II study of 4'epirubicin in advanced squamous cell oesophageal cancer. (1994) (1)
Safety analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan in resected stages II-III rectal cancers (2008) (1)
Adjuvant treatment of colon cancer. A plea for a large-scale European trial. (1994) (1)
Intraperitoneal or intraportal 5 FU combined with systemic chemotherapy for the adjuvant treatment of colorectal cancer: An EORTC (40911) and FFCD (9204) phase III study. (2004) (1)
[Surgical treatment of severe radiation injuries of the small intestine and colon-rectum. Apropos of 85 patients surgically-treated at the Gustave-Roussy Institute]. (1985) (1)
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. (1989) (1)
Gastrointestinal tumors, colorectal (2012) (1)
[Isolated hepatic metastases. Treatment by intra-arterial chemotherapy using a subcutaneous access chamber]. (1986) (1)
Predictive Biomarkers and Personalized Medicine DefectiveMismatchRepair Status asaPrognosticBiomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy (2011) (1)
702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer (1995) (1)
[Cardiotoxicity of 5-fluorouracil. Apropos of a new case]. (1985) (1)
Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as second-line, third-line or later treatment in metastatic colorectal cancer (MCRC) patients (2007) (1)
Unresected hepatic metastases (HM) from colorectal cancer (CRC). Prospective prognostic factor analysis on 544 cases from fondation Française de cancerologie digestive (FFCD) (1993) (1)
HIV Detection in Culture of Peripheral Blood Mononuclear Celts; A Relevant In Vitro Correlate of the Antiviral Effect of ZDV In Vive (1992) (1)
Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005 (2006) (1)
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results]. (1989) (1)
[Intermittent and ambulatory intra-arterial chemotherapy using a subcutaneous access chamber in the treatment of isolated hepatic metastases. Preliminary results]. (1985) (0)
Irinotecan drug eluted beads as a closure treatment for controlled liver colorectal cancer metastases after more than 2 systemic chemotherapy regiments (2014) (0)
05-50 - PREVALENCE OF PATENT FORAMEN OVALE IN CARCINOID SYNDROME AND POTENTIAL USE OF PERCUTANEOUS CLOSURE DEVICE (2008) (0)
Can we use radiofrequency ablation for liver metastases from colorectal cancer over 25 mm initially but downsized by systemic chemotherapy (2015) (0)
[Chemotherapy of digestive cancers]. (1988) (0)
[Evaluation of 242 laparotomies for hepatic metastasis performed at the Institut Gustave Roussy over 5 years]. (1988) (0)
[Biodistribution of murine XF-8 monoclonal antibody in patients with colonic cancer]. (1991) (0)
[Which recommendations for surveillance of patients after colonic or rectal tumor surgery?]. (1998) (0)
[Closure of a large esophagotracheal fistula in esophageal cancer, using two endoprostheses: one tracheobronchial silicone-covered prosthesis and another: expandable silicone-covered metal esophageal prosthesis]. (1996) (0)
Interim efficacy analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan (CPT-11) in resected stages II-III rectal cancers. (2009) (0)
First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228). (2012) (0)
Antitumoral activity of somatostatin analogues (SA) in 34 metastatic and progressive endocrine gastroentero-pancreatic (GEP) tumors (1998) (0)
Reply to E.C. Smyth et al and E. Elimova et al. (2015) (0)
An international multidisciplinary approach to the management of advanced colorectal cancer (First of two parts) (Reprinted from Eur J Surg Oncol, vol 23, Suppl A, August 1997) (1998) (0)
Phase II evaluation of doxorubicin plus amiodarone in advanced hepatocarcinoma. (1991) (0)
302 Equal prognosis of elderly and non-elderly patients with metastatic colorectal cancer and 5-FU treatment: a retrospective analysis (2003) (0)
[Epidermoid cancer of the esophagus. Does the efficacy of chemoradiotherapy justify surgical abstention?]. (1989) (0)
[Usefulness of tumor markers in hepatogastroenterology]. (1989) (0)
Which Intraarterial Hepatic Chemotherapy for Liver Metastasis from Colorectal Carcinoma?1 (1988) (0)
Symptoms Adversely Impact Survival Among Patients With Cancer and Unsuspected Pulmonary Embolism (2011) (0)
Penthiopyrad in the fight against major diseases of pome fruits. (2012) (0)
Cancer du côlon : quel traitement en 2004 ? Le point en cinq questions (2005) (0)
[PET and digestive cancers]. (2008) (0)
[Preoperative chemotherapy (neoadjuvant) of locally advanced gastric cancers]. (1993) (0)
PG 10.03 Lessons from the GASTRIC metaanalysis of adjuvant treatment (2012) (0)
[Long-term results of treatment of chronic active hepatitis B with vidarabine monophosphate]. (1993) (0)
Iconography : Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma (2008) (0)
High incidence of secondary myelodysplastic syndromes following PROMACE‐MOPP and involved field radiotherapy for localized gastric non‐Hodgkin's lymphomas (1996) (0)
[Small hepatocellular carcinoma revealed by peritoneal carcinosis]. (2008) (0)
Long term survival data from EORTC study 40983 : Perioperative chemotherapy for resectable liver metastases from colorectal cancer (2012) (0)
Intra-Arterial Hepatic Chemotherapy for Liver Metastases (1991) (0)
Iconography : An unusual recurrence site for HCC! (2012) (0)
[Which adjuvant treatments and what are their indications following resection for cure in colonic cancer?]. (1998) (0)
The French experience with infusional 5-FU in gastric and pancreatic cancer. (1996) (0)
Peritoneal carcinomatosis treatmnt with curative: Institut Gustave-Roussy experience (1997) (0)
Pharmacokinetic and Pharmacodynamic Advantages of Pirarubicin over Adriamycin after Intraarterial Hepatic Administration in the Rabbit VX 2 T \ imor Model 1 (2006) (0)
[Recent observation of a Corsican family with the thalassemic trait]. (1959) (0)
303 Perioperative treatment – current standards and next steps (2009) (0)
ThyroidIodineContentMeasured byX-RayFluorescence in Amiodarone Induced Thyrotoxicosis: ConciseCommunication (1983) (0)
1030-140 Patent foramen ovale: A new factor associated with progression of carcinoid heart disease (2004) (0)
O-0022COMPARISON OF DOCETAXEL, FLUOROURACIL AND OXALIPLATIN OR CISPLATIN WITH OTHER MODIFIED SCHEDULES: A NEW THERAPEUTIC INDEX IN ADVANCED GASTRIC CANCER (2013) (0)
Folinic acid dose and addition of levamisole does not seem to improve survival or recurrence rates in people treated with adjuvant fluorouracil and folinic acid for colorectal cancer (2000) (0)
[Results of chemotherapy in cancers of the colon]. (1994) (0)
Left-sided valvular disease in carcinoid syndrome: Underestimation without repetitive echocardiographies (2003) (0)
State of the art – colorectal liver metastases (2012) (0)
[Chemotherapy of isolated hepatic metastases. Use of a subcutaneous reservoir for intra-arterial infusions]. (1984) (0)
[Reductional major surgery and chemotherapy in multimetastatic apudomas]. (1988) (0)
P-206Efficacy and tolerance of a simplified combination of Streptozotocin and epi-adriamycin in metastatic foregut neuroendocrine tumor (NET) (2015) (0)
Predictive value of HIV-1 RNA detection in plasma by branched DNA assay during long-term zidovudine therapy (1996) (0)
Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology) (2008) (0)
O-0005 FOLFIRI.3 Alternating with Gemcitabine in Patients with Untreated Metastatic Pancreatic Adenocarcinoma: The Randomized Multicenter Ageo Phase II Trial Firgem (2012) (0)
[Colon and rectal tumours]. (2009) (0)
Chemosensitivity in ovarian metastases from gastric cancer: a case series. (2013) (0)
Métastase pancréatique métachrone d'un adénocarcinome rectal : à propos d'un cas Pancreatic metastasis from a colorectal cancer: a case-report (2011) (0)
[Case report: a voluminous colonic lipoma]. (2008) (0)
DC-beads loaded with irinotecan combined with systemic chemotherapy for pretreated liver dominant metastatic colorectal cancer: Procedure and outcomes of 49 patients (2016) (0)
Renal (Medical) (2006) (0)
Is echocardiographic follow-up of importance in patients presenting with carcinoid tumor and carcinoid syndrome? (2013) (0)
[Value of immunohistochemistry in the study of medullary cancer of the thyroid. Implications of the results for the concept of the APUD system and of apudomas]. (1984) (0)
Medical treatment for peritoneal carcinomatosis from colorectal cancer. (2000) (0)
[Medullary cancer of the thyroid. Clinical forms, diagnostic and therapeutic management]. (1982) (0)
[Gastric lymphoma: natural history and classification]. (1996) (0)
[Colorectal cancer. A better screening, a better treatment]. (2004) (0)
[Combination vindesine, cyclophosphamide, cis-platinum and CCNU in esophageal epidermoid cancer. Preliminary analysis of 64 cases]. (1985) (0)
Intra-hepatic arterial chemotherapy using pirarubicin combined with lipiodol in rabbits bearing VX2 tumors (1993) (0)
Reply to M.J. Rother (2011) (0)
[Judgement criteria in treatments of advanced colorectal cancers and methods of evaluation]. (1997) (0)
[Intra-arterial hepatic chemotherapy. Experience of 200 cases]. (1994) (0)
[Locoregional chemotherapy of hepatic metastases of colorectal cancer]. (1987) (0)
Continuous infusion of 5-fluorouracil (5-FU) in neuroendocrine tumours (NET) (1999) (0)
A Randomized, Double-Blind, Phase (PH) III Study of Folfiri Plus Ramucirumab (RAM) or Placebo (PL) in Patients (Patients) with Metastatic Colorectal Carcinoma (MCRC) Progressed During or Following 1st-Line Therapy with Bevacizumab (BEV), Oxaliplatin (OXALI), and a Fluoropyrimidine (FP) (RAISE) (NCT0 (2012) (0)
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin]. (1986) (0)
[Epidermoid cancer of the esophagus: is the combination of chemotherapy then surgery beneficial?]. (1989) (0)
Multidisciplinary management of rectal cancer with synchronous metastasis (1998) (0)
104Treatment of oesophagus cancer by high dose rate brachytherapy(HDRB) (1998) (0)
Long-term follow-up of patients with the carcinoid syndrome (2011) (0)
[Radiotherapy and combination radiochemotherapy in the treatment of primary cancers of the liver, pancreas and bile ducts]. (1986) (0)
Quality Assurance (2006) (0)
5FU-leucovorin (5FU/LV) with or without irinotecan (CPT-11) in stages II-III rectal cancers: Preliminary safety analysis of the French Intergroup R98 phase III trial. (2004) (0)
Unresectable pancreatic cancer: survival and secondary resections after chemoradiotherapy followed by gemcitabine compared to gemcitabine alone (SFRO/FFCD 2000-01 phase III trial). (2007) (0)
[Management of disclosed hepatic metastases]. (1996) (0)
[Immunoscintigraphy with emission tomography in cancers of the thyroid]. (1984) (0)
[Chemotherapy and surgery: how can resection of colorectal cancer metastases to the liver be optimized?]. (2008) (0)
' s response to reviews Title : Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer : a retrospective study (2009) (0)
[Chemotherapy of digestive neuroendocrine tumors]. (1995) (0)
Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial (2012) (0)
[Advance of chemotherapy and radiotherapy in colorectal cancers]. (1992) (0)
Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer. (1998) (0)
Efficiency of Combined EUS-FNA and Biliary or Duodenal Stenting in Patients with Non Operable Pancreatic Cancer (2009) (0)
32 INVITED Adjuvant treatment of stage II colon cancer (2007) (0)
An unusual recurrence site for HCC! (2013) (0)
6514 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial (2009) (0)
Patients and methods Patients and samples Between 1998 and 2009 , 244 patients underwent hepatic resection for colorectal liver metastasis at the Ambroise Paré Hospital (2012) (0)
Digital superimposition of emission tomography and X-CT images for immunoscintigraphy (1985) (0)
[What is the contribution of tumor response in colorectal cancer?]. (2013) (0)
878 Patent foramen ovale: a new factor associated with progression of right and left carcinoid heart disease (2003) (0)
Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe. (1997) (0)
168 Usefulness of 2D speckle tracking echocardiography in carcinoid heart disease (2010) (0)
Table of Contents for (9781402088995) Methods of Cancer Diagnosis, Therapy and Prognosis: Gastrointestinal Cancer by Hayat, M. A (2011) (0)
Treatment of pancreatic endocrine tumours with adriamycine-streptozotocin association: evaluation of efficacy and prognostic factors of response and survival (2001) (0)
[Small cell bronchial cancer, Schwartz-Bartter syndrome and hyperthyrocalcitonemia. Apropos of 2 cases]. (1974) (0)
18 FDG PET imaging to detect colo-rectal cancer relapse (2006) (0)
[Enteral nutrition in digestive cancer]. (1988) (0)
Letter: Hyperthyrocalcitoninaemia, Schwartz-Bartter syndrome, and oat-cell carcinoma. (1974) (0)
[Conservative treatment undifferentiated neuroendocrine tumors of the anal canal: two cases]. (2007) (0)
Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV-A European multicenter phase II tria (2011) (0)
361Chemotherapy (5 FU-Cis DDP) neoadjuvant and concomitant to irradiation in the conservative treatment of anal canal squamous cell carcinomas larger than 4 cm or with node involvement: Preliminary results on acute toxicity and response (1996) (0)
[Locoregional chemotherapy of hepatic metastases]. (1985) (0)
163 Long-term follow-up of patients with the carcinoid syndrome (2011) (0)
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-fluorouracil and infusional 5-fluorouracil alone in advanced pancreatic carcinoma patients. Authors' reply (2004) (0)
Absence of somatic alterations of the EB1 gene apcassociated protein in human sporadic colorectal cancer (1998) (0)
Moyamoya Disease and Moyamoya Syndrome (2009) (0)
[Secondary appearance of hypoglycemia caused by hyperinsulinism in a patient with malignant endocrine tumor of the pancreas]. (2000) (0)
[Importance of locoregional chemotherapy by anthracyclines]. (1987) (0)
[Interest of a combined modality treatment in unresectable gallbladder carcinoma. A case report]. (2001) (0)
[Ovarian adenocarcinoma, primary or metastasic tumour of an adenocarcinoma of the colon: the role of molecular biology]. (2004) (0)
PG 8.3 Recurrence patterns after resection of liver metastases (2014) (0)
Authors & Collaborators _ RAISE study (2015) (0)
[Treatment of hepatic metastases with unknown primary cancer]. (1985) (0)
[Kaposi-Perrin sarcoma. An uncommon diagnosis in tumor of the rectum]. (1985) (0)
1309 POSTER Care of elderly patients with cancer: place of geriatric intervention (2007) (0)
Epidermoid cancers of the anus. Changes in therapeutic ideas. (1986) (0)
Adénocarcinomes de l’estomac et de la jonction œsogastrique – Approches néoadjuvantes et adjuvantes – le point en 2011 (2011) (0)
[Digestive lymphosarcomas. Apropos of 30 cases]. (1983) (0)
[Palliative chemotherapy in colorectal cancer: new molecular drugs]. (1995) (0)
[A desmoid tumor sensitive to hormonotherapy]. (1994) (0)
Progress in the treatment of gastrointestinal cancer. (2003) (0)
[Management of colorectal cancer and its metastases to the liver]. (2008) (0)
449 Prognosis of carcinoid heart disease: value of tissue Doppler imaging (2006) (0)
Phase II study of fotemustine-5 fulederfoline (FU-FOL) in metastatic colorectal carcinomas (CRC): Preliminary results (1993) (0)
O ral C apecitabine C ompared W ith I ntravenous Fluorouracil P lus L eucovorin i n P atients W ith M etastatic Colorectal C ancer: R esults o f a L arge P hase I II S tudy (2001) (0)
Plans for ISGIO's Fourth Annual GI Oncology Conference Under Way (2007) (0)
Survey of cetuximab activity in irinotecan-refractory metastatic colorectal cancer patients. (2006) (0)
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma. (2012) (0)
[Role of chemotherapy in the treatment of gastric adenocarcinoma]. (1985) (0)
Impact of early tumor response on prognostic of patients with unresectable liver metastases from wt-KRAS colorectal cancer (LM-CRC) treated with hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab after failure of systemic chemotherapy (European Phase II (2016) (0)
Oral diclofenac combined with intra-portal pirarubicin: increased efficacy on liver VX2 tumour and hepatotoxicity in rabbits (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Philippe Rougier?

Philippe Rougier is affiliated with the following schools:

Philippe Rougier's Academic­Influence.com Rankings

Philippe Rougier's Degrees

Why Is Philippe Rougier Influential?

Philippe Rougier's Published Works

Published Works

What Schools Are Affiliated With Philippe Rougier?

Philippe Rougier's AcademicInfluence.com Rankings